# SLA2

## Overview
The SLA2 gene encodes the Src-like adaptor protein 2 (SLAP2), which is a critical component in cellular signaling pathways, particularly within the immune system. SLAP2 is categorized as an adaptor protein, which means it facilitates interactions between other proteins, thereby influencing various signaling cascades. It plays a significant role in modulating T-cell receptor (TCR) signaling, acting as a negative regulator to maintain immune homeostasis and prevent autoimmunity. SLAP2 achieves this by interacting with key signaling proteins and promoting their degradation. Additionally, SLAP2 is involved in the regulation of receptor tyrosine kinases, such as KIT, through its SH2 domain, and is implicated in processes like endocytosis in yeast. The gene's expression and function have clinical significance, particularly in cancer, where it is associated with immune cell infiltration and patient prognosis in head and neck squamous cell carcinoma (Wu2023SLA2; Rupar2018SRClike).

## Function
The SLA2 gene encodes an adaptor protein that plays a crucial role in immune regulation by modulating T-cell receptor (TCR) signaling. In healthy human cells, SLA2 negatively regulates TCR signaling, potentially by interacting with signaling proteins such as ZAP70 and CBL, leading to the degradation of these proteins. This function is essential for maintaining a balance in T-cell activation and preventing overactivation that could result in autoimmunity (Wu2023SLA2).

SLA2 is associated with cellular components like the endosome membrane and is involved in processes such as leukocyte cell-cell adhesion and cytokine receptor activity. These roles suggest that SLA2 is important for maintaining normal immune homeostasis and cellular signaling pathways (Wu2023SLA2). The protein is active in the cytoplasm, where it facilitates interactions between other proteins, playing a role in signal transduction and immune response regulation (Wu2023SLA2).

In the context of cancer, particularly head and neck squamous cell carcinoma, SLA2 is involved in immune cell infiltration within the tumor microenvironment, indicating its broader role in modulating immune responses (Wu2023SLA2).

## Clinical Significance
The SLA2 gene has been implicated in various clinical contexts, particularly in head and neck squamous cell carcinoma (HNSCC). Altered expression levels of SLA2 are associated with patient prognosis in HNSCC, where higher expression correlates with improved overall survival and disease-specific survival. This suggests that SLA2 may serve as an independent prognostic marker in this type of cancer (Wu2023SLA2). The gene's expression is linked to immune cell infiltration in the tumor microenvironment, indicating its potential role in modulating immune responses against tumors (Wu2023SLA2).

SLA2's involvement in immune regulation is further supported by its co-expression with immune-related genes and immune checkpoints, suggesting that it may influence the effectiveness of immune checkpoint blockade therapies (Wu2023SLA2). The gene's expression also correlates with the response to chemotherapeutic agents like cisplatin and methotrexate, where higher SLA2 expression is associated with a lower IC50, indicating increased sensitivity to these drugs (Wu2023SLA2). These findings highlight SLA2's potential as a target for therapeutic interventions in HNSCC and possibly other cancers. However, the clinical significance of SLA2 mutations in other diseases remains less clear, as most studies focus on its expression and interaction profiles.

## Interactions
The SLA2 gene encodes the Src-like adaptor protein 2 (SLAP2), which is involved in various protein interactions that regulate cellular signaling pathways. SLAP2 interacts with receptor tyrosine kinases, such as KIT and its oncogenic mutant KIT-D816V, through its SH2 domain. This interaction is crucial for binding to phosphorylated tyrosine residues on KIT, specifically pY568 and pY570, and is essential for the negative regulation of KIT signaling pathways (Rupar2018SRClike). SLAP2 also associates with the ubiquitin E3 ligase CBL, promoting the ubiquitin-mediated degradation of receptor tyrosine kinases, including KIT and the colony-stimulating factor-1 receptor (CSF1R) (Rupar2018SRClike).

In yeast, the SLA2 homologue, Sla2, interacts with F-actin and the clathrin light chain (CLC) during endocytosis. The interaction between Sla2 and CLC modulates Sla2's binding to F-actin, which is crucial for actin dynamics and endocytic processes (Boettner2011Clathrin). Sla2 also forms complexes with the ENTH domain of epsin through phosphatidylinositol 4,5-bisphosphate (PIP2) lipid interfaces, which are important for clathrin-mediated endocytosis (GarciaAlai2018Epsin).


## References


[1. (GarciaAlai2018Epsin) Maria M. Garcia-Alai, Johannes Heidemann, Michal Skruzny, Anna Gieras, Haydyn D. T. Mertens, Dmitri I. Svergun, Marko Kaksonen, Charlotte Uetrecht, and Rob Meijers. Epsin and sla2 form assemblies through phospholipid interfaces. Nature Communications, January 2018. URL: http://dx.doi.org/10.1038/s41467-017-02443-x, doi:10.1038/s41467-017-02443-x. This article has 49 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-017-02443-x)

[2. (Boettner2011Clathrin) Douglas R. Boettner, Helena Friesen, Brenda Andrews, and Sandra K. Lemmon. Clathrin light chain directs endocytosis by influencing the binding of the yeast hip1r homologue, sla2, to f-actin. Molecular Biology of the Cell, 22(19):3699–3714, October 2011. URL: http://dx.doi.org/10.1091/mbc.e11-07-0628, doi:10.1091/mbc.e11-07-0628. This article has 38 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1091/mbc.e11-07-0628)

[3. (Wu2023SLA2) Zhongbiao Wu, Chengkun You, Zhongyan Zhu, Weikun Wu, Jian Cao, Qiang Xie, Chengcheng Deng, Xinmei Huang, and Shiping Hu. Sla2 is a prognostic marker in hnscc and correlates with immune cell infiltration in the tumor microenvironment. European Archives of Oto-Rhino-Laryngology, 281(1):427–440, September 2023. URL: http://dx.doi.org/10.1007/s00405-023-08213-4, doi:10.1007/s00405-023-08213-4. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00405-023-08213-4)

[4. (Rupar2018SRClike) Kaja Rupar, Sausan A. Moharram, Julhash U. Kazi, and Lars Rönnstrand. Src-like adaptor protein 2 (slap2) is a negative regulator of kit-d816v-mediated oncogenic transformation. Scientific Reports, April 2018. URL: http://dx.doi.org/10.1038/s41598-018-24743-y, doi:10.1038/s41598-018-24743-y. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-018-24743-y)